Step 1 of 2
Review these downloadable slides on treatment sequencing, mechanisms of acquired resistance, and adverse event management in patients with atypical EGFR-mutated NSCLC. Current guideline recommendations and clinical trial evidence supporting subsequent-line treatment strategies for patients with uncommon EGFR mutations or EGFR exon 20 insertions are highlighted. Key findings from the CHRYSALIS-2, MARIPOSA-2, TROPION-Lung01/05, WU-KONG1B, and REZILIENT1 trials provide efficacy and safety data for amivantamab-based regimens, datopotamab deruxtecan, sunvozertinib, and zipalertinib. The slides also address the role of repeat molecular testing in identifying resistance mechanisms, considerations for managing CNS metastases, and strategies to prevent and manage treatment-related toxicities, including dermatologic adverse events, infusion-related reactions, venous thromboembolism, and stomatitis, to support individualized treatment decisions and continuity of care.